Online inquiry

IVTScrip™ mRNA-Anti-CD3E&MS4A1, REGN-1979(Cap 0, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13877MR)

This product GTTS-WQ13877MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets CD3E&MS4A1 gene. The antibody can be applied in Chronic lymphocytic leukemia (CLL), Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000733.4; NM_021950.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 931
UniProt ID P07766; P11836
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&MS4A1, REGN-1979(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ13877MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ9284MR IVTScrip™ mRNA-Anti-TACSTD2, IMMU-132(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA IMMU-132
GTTS-WQ2641MR IVTScrip™ mRNA-Anti-IL2RB, AMG 592(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AMG 592
GTTS-WQ13288MR IVTScrip™ mRNA-Anti-PTK7, PF-06523435(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA PF-06523435
GTTS-WQ4324MR IVTScrip™ mRNA-Anti-C1S, BIVV009(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BIVV009
GTTS-WQ14951MR IVTScrip™ mRNA-Anti-PDCD1, SHR-1210(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA SHR-1210
GTTS-WQ5940MR IVTScrip™ mRNA-Anti-IGHE, CL-2C(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA CL-2C
GTTS-WQ4444MR IVTScrip™ mRNA-Anti-CTLA4, BMS-734016(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA BMS-734016
GTTS-WQ11865MR IVTScrip™ mRNA-Anti-TIGIT, MK-7684(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MK-7684
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW